Category: press statement – en

Eternygen's collaborator Naomi Dirckx from University of Maryland, Baltimore presents most recent data about “The longevity transporter SLC13A5 as a [...]

Eternygen founder Prof. Birkenfeld published exciting work about pre-diabetes in The Lancet Diabetes & Endocrinology. Find the article here. Find [...]

In collaboration with Dipender Gill and Stephen Burgess, we've identified a noteworthy new connection between hepatic INDY/SLC13A5 and kidney function. This [...]

Meet the Eternygen team at the “Aging research and drug discovery meeting” in Copenhagen from 28 Aug to 1 Sep [...]

Eternygen´s founder Prof. Andreas Birkenfeld discusses 10 common prejudices about obesity. (in German) Find the video here.

Meet Eternygen at BioEuropeSpring conference in Basel from 20-22 March 2023 More information here.

Meet Eternygen at BioEurope conference in Leipzig from 23-26 October 2022 More information here.

Grit Zahn, Head of Research of Eternygen GmbH will be speaking at TESS Research Foundation's International Research Conference in Vienna [...]

Meet the Eternygen team at the “Aging research and drug discovery meeting” in Copenhagen from August 28th to 1 September. [...]

Eternygen published new paper on SLC13A5 inhibitors titled: “A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis [...]

Andreas Birkenfeld and Dr. Grit Zahn are Guest editing a Special Issue on “I'm Not Dead Yet in Metabolic Regulation” [...]

Eternygen Announces the First Closing of its Series A2 Funding Round

News of Eternygen

Eternygen is presenting at „BioLaunchPad, the company showcase platform of BioTrinity” from 28 April – 1 May 2020. Link

Dr. Grit Zahn, Head of Research of Eternygen GmbH presents at the 4th International SLC13A5 Deficiency Research Roundtable of the […]

Eternygen Presents Data Demonstrating INDY Inhibition as Novel Therapeutic Option in NASH Press statement

Meet Eternygen at the Biotech Showcase conference 2020 in San Francisco, CA, USA Eternygen is attending the Biotech Showcase conference […]

Meet Eternygen at BioEurope conference in Hamburg from November 11th to 13th Eternygen will attend the BioEurope conference in Hamburg […]

Prof. Birkenfeld was appointed as Chair of Medicine and Director of the Department of Diabetology, Endocrinology and Nephrology at the […]

Prof. Birkenfeld was awarded with the Abstract Award Prof. Birkenfeld was awarded with the Abstract Award by the American College […]

Eternygen at BioFIT 2017 Eternygen was invited to join panel discussion at BioFIT 2017 conference “How are collaborations key to […]

Prof. Birkenfeld is chairman of the working group diabetes and heart Prof. Birkenfeld is the new chairman of the working […]

Eternygen GmbH is part of the Network for Pharma Solutions (NetPhaSol, Germany) Press release

Eternygen GmbH closes € 8.0 (US$ 8.3) million Series A financing Eternygen GmbH Closes € 8.0 (US$ 8.3) million Series […]

Prof. Jordan takes on position as Head of the Institute of Aerospace Medicine “Prof. Jordan takes on position as Head […]

TransCampus Network between TU Dresden and King’s College London receives €5million grant The TransCampus network between King’s and Technische Universität […]

Eteryngen at 7th International IQPC Conference Eternygen GmbH today announced that its head of research will present at the 7th International […]

Prof. Birkenfeld to take over the succession of Prof. Markolf Hanefeld at centre of clinical studies in Dresden Interview by […]

Prof. Jordan receives renowned Peter Sleight Award Prof. Jordan receives renowned Peter Sleight Award of the european society of Hypertension […]

Prof. Birkenfeld to receive renowned Ferdinand Bertram price Press statement of GWT (in German) Article in Sächsische Zeitung (in German)